Vendor Intelligence Report: Nantong Guangyuan Chemical GYC

Published 13 Jun 2026. 20-page investigative report on who is behind Nantong Guangyuan Chemical GYC: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 41 Finnrick lab tests, the overall pass rate is 93% (38 pass / 3 fail). Nantong Guangyuan Chemical GYC is not a simple “good vendor/bad vendor” case. The tested catalog is narrow: only Retatrutide and Tirzepatide appear in the record, and both show a reasonable historical sample-quality signal, with Retatrutide modestly ahead. The ratings shrink under stricter grading when vial-content precision matters more than simple pass/fail.

The larger buyer hazard is authentication. The file separates a real Nantong trading company and Lisa-led peptide-community presence from a live clone environment. One clone site copied GYC branding, carried a near-match Telegram handle, and used fake verification/social-proof signals; community reports describe payments taken with no package sent. Finnrick’s March 2026 correction retracted GYC tests and assigned a fraud designation because the GYC name had become part of the attack surface.

Corporate records are also narrower than the marketing language suggests. Independent B2B directories support a legitimate Nantong Guangyuan Chemical entity, but characterize it as a small trading/distribution company rather than a verified manufacturer. Direct Chinese registry fields remain unresolved, and the official web/channel setup is fragile: login-gated catalog access, changing Discord invites, and warehouse claims not verified in this cycle.

The practical read: authenticated, independently verified GYC Retatrutide and Tirzepatide lots have a better historical lab profile than a fail-heavy vendor, but new purchases through search results, copied Discord invites, clone domains, or lookalike Telegram accounts remain poor-risk. The full report shows exactly where the evidence line falls.

Inside the full report:

  • Per-product pass/fail rates, rating trajectories, and methodology-divergence charts for both tested products
  • Official-versus-clone channel comparison covering domains, email, Telegram, Discord, and verification badges
  • RDAP, DNS, IP, registrar, and archive analysis for ggpeps.com, ggpeps.net, gycpeptides.net, and related domains
  • Forensic review analysis showing backdated customer reviews and repeated templated trust signals on the clone site
  • Corporate-identity review using B2B directories, unresolved Chinese registry fields, and trading-company indicators
  • Authentication guide for separating genuine GYC channels from fraud infrastructure before any payment is sent

Risk assessment

  • Impersonation and payment-loss risk — high: ggpeps.net, gycpeptides.net and Telegram @glisa8 impersonate GYC; community reports describe payments taken with no packages sent.
  • Fake verification and review-manipulation risk — high: ggpeps.net uses PeptideMeter.com, identified by Finnrick as a fraudulent Finnrick copy, and hosts backdated reviews that predate the domain registration.
  • Channel-authentication instability risk — medium: Legitimate anchors exist (ggpeps.com, info@ggpeps.com, @Glisa888), but ggpeps.com is login-gated and GYC Discord links changed after reported raids.
  • Product-specific fill/methodology-sensitivity risk — medium: Tested Retatrutide (89.36%, 17/18 pass) and Tirzepatide (87.81%, 21/23 pass) perform reasonably under public Purity Focus, but 3 failures and stricter-methodology divergence keep vial-content precision material.